TY - JOUR
T1 - Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy
AU - Matsushita, Maiko
AU - Kawaguchi, Mai
N1 - Funding Information:
This work received funding from Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research. We are thankful to Ms. Saori Matsumoto, Mr. Sho Kashiwazaki, and Mr. Michio Kobori for their suggestions about drugs related to immunogenic cell death. We are also thankful to Dr. Yutaka Hattori and Dr. Daiju Ichikawa for their valuable feedbacks.
Publisher Copyright:
© 2018 Maiko Matsushita and Mai Kawaguchi.
PY - 2018
Y1 - 2018
N2 - Recent advances in cancer immunotherapy, including immune checkpoint inhibitors or adoptive T cell therapies, have contributed to better outcomes in cancer patients. However, there are still many cancers with no cure. Therefore, combinations of several treatment strategies are being explored, and enhancing anticancer immunity will play an important role to combat the disease. There have been several reports on the immune-modulatory effects of commonly used drugs, namely, statin, metformin, and angiotensin receptor blockers (ARBs), which suggest that these drugs could enhance immunity against cancer cells. Other anticancer drugs, such as anthracyclines, thalidomides, lenalidomides, and hypomethylating drugs, could also strengthen the immune system to attack cancer cells at a relatively low dose. Hence, these drugs might contribute to better outcomes in cancer patients.
AB - Recent advances in cancer immunotherapy, including immune checkpoint inhibitors or adoptive T cell therapies, have contributed to better outcomes in cancer patients. However, there are still many cancers with no cure. Therefore, combinations of several treatment strategies are being explored, and enhancing anticancer immunity will play an important role to combat the disease. There have been several reports on the immune-modulatory effects of commonly used drugs, namely, statin, metformin, and angiotensin receptor blockers (ARBs), which suggest that these drugs could enhance immunity against cancer cells. Other anticancer drugs, such as anthracyclines, thalidomides, lenalidomides, and hypomethylating drugs, could also strengthen the immune system to attack cancer cells at a relatively low dose. Hence, these drugs might contribute to better outcomes in cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=85056218658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056218658&partnerID=8YFLogxK
U2 - 10.1155/2018/8653489
DO - 10.1155/2018/8653489
M3 - Review article
AN - SCOPUS:85056218658
SN - 1687-8450
VL - 2018
JO - Journal of Oncology
JF - Journal of Oncology
M1 - 8653489
ER -